Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacodynamics and Immunogenicity of Universal CNK-UT Cells in Patients With Advanced Solid Tumors.

NCT05976906 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05976906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacodynamics and Immunogenicity of Universal CNK-UT Cells in Patients With Advanced Solid Tumors.
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
May 23, 2023
Completion date
September 30, 2025
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors